Oncology

• 
• 
• 
• 

Despite the success of immune checkpoint inhibitors (ICI) like anti-PD-1 in treating other cancers, these therapeutics have not been demonstrated to effectively treat acute myeloid leukemia (AML). Vanderbilt researchers have identified PD-1H as a potential target for treating AML, opening the door for effective therapy using an ICI molecule.

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).

The sheer volume of medical information available to physicians today is overwhelming. Diagnostic Management Team provides a concise, accurate method for ordering the correct diagnostic tests every time, and it returns the results in a uniform report format, easily read by the physician. This has already been launched within Vanderbilt University, with a high adoption rate amongst physicians and has already shown significant savings.

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.